Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new triple-hormone receptor agonist, retatrutide, dramatically cut sleep apnea severity in two phase 3 trials — with or without type 2 diabetes. At 80 weeks, over half of non-diabetic patients on the 9 mg dose achieved remission or mild OSA without daytime sleepiness, compared to just 12.5% on placebo. Experts say weight-loss drugs are reshaping OSA treatment, though CPAP may still be needed for many patients.
Eli Lilly's investigational drug retatrutide — a triple GIP, GLP-1, and glucagon receptor agonist — significantly reduced obstructive sleep apnea (OSA) severity in two phase 3 trials (TRIUMPH-1-OSA and TRIUMPH-2-OSA), published in the New England Journal of Medicine. The trials enrolled adults with moderate-to-severe OSA and BMI ≥27, both with and without type 2 diabetes, and followed them for 80 weeks. Retatrutide also delivered substantial weight loss of ~18–22%, and meaningfully reduced the sleep apnea-specific hypoxic burden — a marker tied to cardiovascular risk — by 63–75% across both trials.
This builds on a growing body of evidence for GLP-1-based therapies in OSA. Earlier data from tirzepatide's SURMOUNT-OSA trials, reviews of multiple GLP-1 agents, and real-world studies all point to significant reductions in OSA incidence and cardiovascular risk with these medications. Experts note that while GLP-1 drugs are a meaningful advance — especially for patients who struggle with sustained weight loss — residual OSA persists in roughly half of patients, and CPAP remains the gold standard for symptom control.
By the Numbers:
Why it matters: Retatrutide could become a powerful new tool for the millions of people with obesity-related OSA, particularly those who can't tolerate CPAP. But experts caution that weight loss alone doesn't guarantee OSA resolution — repeat sleep testing after significant weight loss remains essential to guide treatment decisions.
